The study used central venous pressure greater than 12 cmH2O as the cutoff point for adequate intravascular volume prior to initiating the study protocol.
As part of her BMedSci, KG initiated the study protocol, collected and analysed the data, and wrote the first draft of the manuscript.
Before the study was initiated, the study protocol, the Informed Consent Form and Subject Information were submitted to the responsible independent ethics committee of the Aerztekammer Nordrhein, Duesseldorf, Germany for review and it was approved on 02 May 2008.
Prior to initiating the study, the protocol was approved by the Iowa State University Institutional Animal Care and Use Committee IACUCC 8-11-7187-B) and the Institutional Biosafety Committee (IBC 11-D-0017-A).
Confirmed repeat urine albumin-to-creatinine ratios ≥30 μg/mg were required to initiate ACE therapy using the study protocol for lisinopril ACE therapy with protocol-driven dosage adjustments made until the albumin-to-creatinine ratio fell to <30 μg/mg at a consecutive visit.
YAZ, DC and MJ initiated the study, developed the study protocol, analysed and interpreted the data and wrote the manuscript.
ALH initiated the study and developed the study protocol.
The study protocol (initiated in July 2000) was approved by the institutional review board of the National Institute of Diabetes and Digestive and Kidney Diseases.
Alexander E Berezin initiated the hypothesis and designed the study protocol, contributed to collect, analyze and interpret the data, performed statistical analysis, wrote the manuscript.
FTB initiated the project and completed the study protocol; FTB, WB, MB, SM, JZ and EMZ developed the concept of the project and FTB and WB will direct the study; MB SM and JZ will provide access to patients; EMZ and FTB will implement the protocol, acquire and analyze data; all authors read and approved the final manuscript.
